Endeavor’s taladegib shows first signs of reversing lung fibrosis in phase 2b trial
Endeavor BioMedicines reported that its Hedgehog inhibitor taladegib met primary endpoints in a phase 2b trial for idiopathic pulmonary fibrosis, showing improved lung function and reduced fibrosis. The results suggest the drug could reverse disease progression, challenging current standard-of-care therapies that only slow decline.
Key points
- The WHISTLE-PF trial included 213 patients with idiopathic pulmonary fibrosis and met its primary endpoint at 24 weeks.
- Taladegib demonstrated statistically significant improvements in percent predicted forced vital capacity compared to placebo.
- The drug showed sustained improvements in lung function and significant reductions in biomarkers for total lung capacity and lung fibrosis.
- Serious adverse event rates were balanced between the taladegib and placebo groups.
- Endeavor plans to engage with the FDA regarding a phase 3 strategy following these results.
Background
Current treatments for idiopathic pulmonary fibrosis, such as Boehringer Ingelheim’s Ofev and Roche’s Esbriet, are designed to slow the decline of lung function rather than reverse it. Endeavor’s earlier phase 2a data in 2024 also suggested potential benefits by targeting specific fibroblasts. Recent archive coverage noted other experimental approaches, such as rentosertib, which showed biomarker changes suggesting biological aging reversal in a small preliminary study, but taladegib is the first to report phase 2b data indicating actual reduction in fibrosis.
How outlets are covering it
Fierce Biotech emphasizes the potential for taladegib to supplant incumbent drugs by reversing disease rather than just slowing progression. Endpoints News confirms the mid-stage trial success but notes the article is behind a paywall, limiting detailed analysis. FirstWord Pharma’s source was inaccessible due to a JavaScript error, so no perspective could be extracted. All available sources agree on the positive outcome of the WHISTLE-PF trial, with Fierce Biotech providing the most detailed breakdown of the biomarker improvements and safety profile.
Why it matters
If confirmed in phase 3, taladegib could become the first treatment to actively reduce lung fibrosis, offering a new therapeutic option for a disease with limited current treatments. This could significantly impact the market share of established players and provide hope for patients suffering from this progressive condition.
What to watch
Endeavor BioMedicines will engage with the FDA to determine the strategy for phase 3 trials. Detailed data from the WHISTLE-PF trial is expected to be presented at a future medical meeting.
- Endeavor’s threat to IPF incumbents increases after phase 2 win for Hedgehog inhibitor Fierce Biotech
- Endeavor notches major mid-stage trial win, says IPF drug can reverse disease Endpoints News
- Endeavor BioMedicines' WHISTLE-PF Phase 2b Trial of Taladegib Meets Primary and Key Secondary Endpoints in Patients With IPF Business Wire
- Endeavor to move IPF hopeful into Phase III after mid-stage victory FirstWord Pharma
- Endeavor’s Phase IIb IPF study of taladegib meets endpoints Clinical Trials Arena
Want the full story? Read the original reporting
Read on Fierce Biotech